News
-
-
COMMUNIQUÉ DE PRESSE
Moderna Reports Third Quarter 2024 Financial Results and Provides Business Updates
Moderna, Inc. reports Q3 revenue of $1.9B, net income of $13M, and EPS of $0.03. Initiates Phase 3 trials for mRNA vaccines, reiterates 2024 sales guidance. Announces expansion of Executive Committee -
-
-
COMMUNIQUÉ DE PRESSE
Moderna to Present at Upcoming Conferences in November 2024
Moderna, Inc. to participate in upcoming investor conferences: Guggenheim's Healthcare Innovation Conference, UBS Global Healthcare Conference, Jefferies London Healthcare Conference. Moderna leading in mRNA medicine technology for disease treatment and prevention -
-
-
-
-
